Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).

MASH is a significant obesity-related complication.

Semaglutide shows promise in treating MASH.

Weight loss is crucial for improving liver health.

Bariatric surgery remains the most effective treatment.

The Essence trial indicates a 63% resolution of NASH.

New medications are being developed for obesity treatment.

Early intervention is key to preventing severe liver damage.

Accessibility of medications is a major concern.

Comparative studies are essential for evaluating new treatments.

Future treatments may include innovative delivery methods.